216 related articles for article (PubMed ID: 1880564)
1. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
2. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.
Ichiya Y; Kuwabara Y; Sasaki M; Yoshida T; Omagari J; Akashi Y; Kawashima A; Fukumura T; Masuda K
Ann Nucl Med; 1996 May; 10(2):193-200. PubMed ID: 8800448
[TBL] [Abstract][Full Text] [Related]
3. [The role of diagnostic PET in treatment planning before tumor surgery].
Haberkorn U
Chirurg; 2001 Sep; 72(9):1010-9. PubMed ID: 11594269
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
[TBL] [Abstract][Full Text] [Related]
6. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.
Patz EF; Lowe VJ; Hoffman JM; Paine SS; Harris LK; Goodman PC
Radiology; 1994 May; 191(2):379-82. PubMed ID: 8153309
[TBL] [Abstract][Full Text] [Related]
7. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
8. [Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma].
Ukena D; Hellwig D; Palm I; Rentz K; Leutz M; Hellwig AP; Kirsch CM; Sybrecht GW
Pneumologie; 2000 Feb; 54(2):49-53. PubMed ID: 10731756
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
10. Development of oncology protocol using fluorine-18-FDG: one center's experience.
Cronin V; Galantowicz P; Nabi HA
J Nucl Med Technol; 1997 Mar; 25(1):66-9. PubMed ID: 9239608
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose].
Fukunaga T; Enomoto K; Okazumi S; Kikuchi T; Yamamoto H; Koide Y; Isono K
Nihon Geka Gakkai Zasshi; 1994 May; 95(5):317-25. PubMed ID: 8007937
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis of early cancer with positron emission tomography].
Kubota K
Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
[TBL] [Abstract][Full Text] [Related]
13. Detecting recurrent or residual lung cancer with FDG-PET.
Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET for the evaluation of tumor viability after anticancer therapy.
Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
[TBL] [Abstract][Full Text] [Related]
15. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
16. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.
Janus TJ; Kim EE; Tilbury R; Bruner JM; Yung WK
Ann Neurol; 1993 May; 33(5):540-8. PubMed ID: 8498831
[TBL] [Abstract][Full Text] [Related]
17. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
18. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.
Keogan MT; Lowe VJ; Baker ME; McDermott VG; Lyerly HK; Coleman RE
Abdom Imaging; 1997; 22(3):332-7. PubMed ID: 9107663
[TBL] [Abstract][Full Text] [Related]
19. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
[TBL] [Abstract][Full Text] [Related]
20. Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET.
Hunter GJ; Choi NC; McLoud TC; Fischman AJ
J Nucl Med; 1993 Sep; 34(9):1571-3. PubMed ID: 8394885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
